MBM-17
- CAS No.
- 2083621-90-1
- Chemical Name:
- MBM-17
- Synonyms
- MBM-17;MBM 17,MBM17;Benzamide, 4-[7-[1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2-(phenylmethoxy)-
- CBNumber:
- CB65821204
- Molecular Formula:
- C28H28N6O2
- Molecular Weight:
- 480.56
- MDL Number:
- MFCD32174238
- MOL File:
- 2083621-90-1.mol
- MSDS File:
- SDS
MBM-17 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | IID62190 | MBM 17 | 2083621-90-1 | 5mg | $1670.55 | 2026-06-04 | Buy |
| Biosynth | IID62190 | MBM 17 | 2083621-90-1 | 10mg | $2672.8 | 2026-06-04 | Buy |
| Biosynth | IID62190 | MBM 17 | 2083621-90-1 | 25mg | $5011.5 | 2026-06-04 | Buy |
| Biosynth | IID62190 | MBM 17 | 2083621-90-1 | 50mg | $8018.5 | 2026-06-04 | Buy |
MBM-17 Chemical Properties, Uses, Production
Uses
MBM-17 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM. It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice[1].
in vivo
MBM-17 (20 mg/kg; i.p.; twice a day for 21 days) exhibits good antitumor activity and a well-tolerated dose schedule[1].
MBM-17 (1.0 mg/kg; i.v.) treatment shows CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 42.4 mL/min/kg, 4.06 L/kg, 2.42 hours, 386 ng/h/mL, and 405 ng/h/mL, respectively[1].
| Animal Model: | Female BALB/c nu/nu mice (5-6 weeks, bearing HCT-116 xenografts)[1] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection; twice a day for 21 days |
| Result: | Tmor growth was significantly suppressed. |
| Animal Model: | Male Sprague Dawley (SD) rats[1] |
| Dosage: | 1.0 mg/kg |
| Administration: | IV injection (Pharmacokinetic Analysis) |
| Result: | The CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 42.4 mL/min/kg, 4.06 L/kg, 2.42 hours, 386 ng/h/mL, and 405 ng/h/mL, respectively. |
IC 50
NEK2: 3 nM (IC50)
References
[1] Xi JB, et al. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem. 2017 Jan 27;126:1083-1106. DOI:10.1016/j.ejmech.2016.12.026
MBM-17 Preparation Products And Raw materials
Raw materials
Preparation Products
MBM-17 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Sichuan Wei Keqi Biological Technology Co., Ltd. | 028-81700200 18116577057 | 3003855609@qq.com | China | 7717 | 56 |
| Fan De(Beijing) Biotechnology Co., Ltd. | 15911056312 | liming@bio-fount.com | China | 9718 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 38999 | 58 |
| TargetMol Chemicals Inc. | 13564774135 | marketing@targetmol.com | United States | 19950 | 58 |
